Anzeige
Mehr »
Montag, 01.09.2025 - Börsentäglich über 12.000 News
Wie SuperBuzz am Freitag parabolisch durchstartete - und warum das erst der Anfang sein könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QGE7 | ISIN: US04683R1068 | Ticker-Symbol:
NASDAQ
29.08.25 | 21:26
3,345 US-Dollar
-3,60 % -0,125
1-Jahres-Chart
ATEA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ATEA PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur ATEA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08.08.Atea Pharmaceuticals Q2 2025 slides: HCV program advances with Phase 3 trials underway5
07.08.Atea Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
07.08.Atea Pharmaceuticals, Inc. - 10-Q, Quarterly Report3
ATEA PHARMACEUTICALS Aktie jetzt für 0€ handeln
07.08.Atea Pharmaceuticals, Inc. - 8-K, Current Report2
24.06.Atea Pharmaceuticals, Inc.: Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America148C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class...
► Artikel lesen
20.06.Atea Pharmaceuticals, Inc. - 8-K, Current Report3
12.05.Atea Pharmaceuticals GAAP EPS of -$0.40 beats by $0.013
12.05.Atea Pharmaceuticals, Inc. - 10-Q, Quarterly Report3
12.05.Atea Pharmaceuticals, Inc. - 8-K, Current Report1
12.05.Atea Pharmaceuticals, Inc.: Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update151Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Supporting...
► Artikel lesen
23.04.Atea Pharmaceuticals, Inc.: Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 20251
17.04.Atea Pharmaceuticals announces share repurchase program1
17.04.Atea Pharmaceuticals, Inc. - 8-K, Current Report1
17.04.Atea Pharmaceuticals erweitert Vorstand und genehmigt Aktienrückkauf3
17.04.Atea Pharmaceuticals, Inc.: Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program2
09.04.Atea Pharmaceuticals Doses First Patient In Phase 3 Trial For Chronic Hepatitis C Treatment1
09.04.Atea Pharmaceuticals, Inc.: Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus104Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect HCV Infection Remains a Significant Global Health...
► Artikel lesen
01.04.Atea Pharmaceuticals, Inc. - 8-K, Current Report4
26.03.Atea Pharmaceuticals ergreift Maßnahmen zur Steigerung des Aktionärswerts3
26.03.Atea Pharmaceuticals takes steps to boost shareholder value1
Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1